Hold onto your hats, baseball fans, because the New York Mets are shaking things up this offseason! According to Jeff Passan of ESPN, the team is reportedly shopping some of its biggest names, including Kodai Senga, Brandon Nimmo, and Jeff McNeil. But here's where it gets controversial—are the Mets dismantling a core group of players who could still contribute, or are they strategically clearing the deck for a rebuild? Let’s dive into the details and see what’s really at stake.
Passan’s offseason preview highlights that the Mets aren’t just dangling prospects like Luisangel Acuña, Mark Vientos, or Brett Baty—they’re putting established stars on the table. For starters, Brandon Nimmo, a first-round pick from 2011, has been a Mets lifer. At 32, he’s coming off a solid season where he slashed .262/.324/.436 with a career-high 25 home runs. His 114 wRC+ and 3.0 fWAR marked improvements over his 2024 performance, and he’s got five years left on his eight-year, $162 million deal—complete with a full no-trade clause. But would he waive it? And if so, where might he land?
Then there’s Kodai Senga, whose transition from Japan to MLB was nothing short of spectacular in 2023. He logged 166.1 innings with a 2.98 ERA and a 3.63 FIP, finishing second in NL Rookie of the Year voting and seventh in Cy Young consideration. His 4.5 bWAR ranked third among NL pitchers that year, and his ERA was second-best. But here’s the part most people miss—since then, injuries have derailed his career. After a disastrous 2024 postseason and a 2025 season limited to just 113.1 innings, Senga’s health is a major question mark. His 3.02 ERA this year is impressive, but it’s skewed by a 5.90 ERA in nine starts post-hamstring injury. With two years left on his $75 million contract, is he still a high-value trade chip, or is his stock plummeting?
And let’s not forget Jeff McNeil, another Mets lifer who burst onto the scene in 2018 as a high-average hitter. His first three seasons were stellar, culminating in a 2019 All-Star nod and a .319/.383/.501 line through 2020. But his performance has been inconsistent since. After winning the NL batting title in 2022 with a .326/.382/.454 line and a 140 wRC+, he dipped below league average in 2023 and 2024 before rebounding slightly in 2025 with a 111 wRC+. However, Thoracic Outlet Syndrome has become a looming concern. With just one year left on his $50 million deal, is McNeil still a valuable asset, or is his best baseball behind him?
Here’s the million-dollar question: Are the Mets making a smart move by trading these players now, or are they undervaluing what they have? Senga’s injury history, Nimmo’s no-trade clause, and McNeil’s inconsistency all complicate matters. But if they can find the right deals, the Mets could free up significant payroll and rebuild their roster. What do you think? Are these trades a necessary step forward, or is the organization giving up too soon? Let us know in the comments—this is one debate that’s sure to heat up as the offseason unfolds.
